What are the appropriate dosing, monitoring parameters, contraindications, and alternative therapies for unfractionated heparin (UFH) in adult patients?

Unfractionated Heparin (UFH): Dosing, Monitoring, and Clinical Management

For adult patients requiring UFH anticoagulation, initiate with a weight-based bolus of 60-80 U/kg (maximum 4000-5000 U) followed by continuous infusion of 12-18 U/kg/hour (maximum 1000-1250 U/hour), with dose adjustments targeting aPTT 1.5-2.5 times control (60-85 seconds) or anti-Xa levels of 0.30-0.70 IU/mL. 1, 2

Dosing Regimens by Indication

Venous Thromboembolism (VTE)

• IV bolus: 80 U/kg followed by 18 U/kg/hour infusion 3
• Alternative: 60 U/kg bolus (max 4000 U) followed by 12 U/kg/hour (max 1000 U/hour) 1
• Subcutaneous option: 333 U/kg initial dose, then 250 U/kg twice daily (unmonitored) 3

Important caveat: While UFH remains an option for VTE, LMWH or fondaparinux are preferred (grade 2C) due to more predictable pharmacokinetics and lower HIT risk 3. Reserve UFH for patients requiring rapid reversibility, severe renal impairment (CrCl <30 mL/min), or high bleeding risk 4.

Acute Coronary Syndromes (ACS)

• NSTE-ACS initial therapy: 60 IU/kg bolus (max 4000 IU), then 12 IU/kg/hour infusion (max 1000 IU/hour), adjusted to aPTT 60-80 seconds 1
• To support PCI: 70-100 U/kg bolus to achieve ACT 250-300 seconds in anticoagulant-naive patients 1
• With fibrinolytic therapy: 60 IU/kg bolus (max 4000 IU), then 12 IU/kg/hour (max 1000 IU/hour) 1, 5

Pediatric Dosing

• Loading dose: 75-100 units/kg IV over 10 minutes 4, 2
• Maintenance infusion:
  • Infants <1 year: 28 IU/kg/hour 4
  • Children 1-15 years: 20 IU/kg/hour 4
  • Children ≥15 years: 18 IU/kg/hour 4
• Target: aPTT 60-85 seconds or anti-Xa 0.35-0.70 IU/mL 4, 2

Critical point: Use preservative-free formulations in neonates and infants to avoid benzyl alcohol toxicity 2.

Monitoring Parameters

Laboratory Monitoring Strategy

The anti-Xa assay is emerging as the preferred monitoring method over aPTT due to less interference from coagulation factor abnormalities, acute phase reactants, and lupus anticoagulants 6, 7, 8. However, aPTT remains widely used and acceptable when properly validated.

aPTT Monitoring

• Therapeutic range: 1.5-2.5 times control (approximately 50-85 seconds) 3, 1, 9, 2
• Timing: Check baseline, then every 4 hours after initiation or dose change until stable, then daily 2
• Critical limitation: Each institution must establish a local therapeutic range correlating with anti-Xa levels of 0.30-0.70 IU/mL, as reagent sensitivity varies significantly 3, 9, 6

Anti-Xa Monitoring

• Therapeutic range: 0.30-0.70 IU/mL 3, 1, 3, 9, 2, 6
• Advantages: Not affected by factor VIII elevations, lupus anticoagulants, or factor deficiencies 4, 6
• Preferred assays: Those without dextran sulfate or added antithrombin 6

Safety Monitoring

• Platelet counts: Every 2-3 days from day 4 to day 14 to screen for HIT (risk up to 5% with UFH) 3, 2
• Hematocrit and occult blood: Periodically throughout therapy 2
• Baseline: aPTT, INR, platelet count, hemoglobin/hematocrit 2

Dose Adjustment Protocol

Use weight-based nomograms with the following general approach 4, 3:

aPTT (seconds)	Anti-Xa (IU/mL)	Action
<50	<0.1	Bolus 50 U/kg, increase rate by 20%
50-59	0.1-0.29	Increase rate by 10%
60-85	0.35-0.70	No change (therapeutic)
86-95	0.71-0.90	Decrease rate by 10%
96-120	0.91-1.0	Hold 30 min, decrease rate by 10%
>120	>1.0	Hold 60 min, decrease rate by 20%

Recheck levels 4 hours after any rate change 4.

Contraindications and Precautions

Absolute Contraindications

• Active major bleeding
• Severe thrombocytopenia (platelet count <20,000/μL)
• History of HIT with positive antibodies
• Hypersensitivity to heparin or pork products 2

Relative Contraindications/High-Risk Situations

• Recent neurosurgery, spinal surgery, or ophthalmologic surgery
• Uncontrolled severe hypertension
• Bacterial endocarditis
• Severe liver disease with coagulopathy 3
• Hemophilia or other bleeding disorders 2

Special Populations

Renal Impairment

• CrCl <30 mL/min: UFH is preferred over LMWH as it does not accumulate 3
• No dose adjustment needed for UFH itself 2

Obesity and Elderly

• Weight >100 kg or age ≥65 years: Consider using adjusted body weight (AdjBW) rather than total body weight for dosing calculations to reduce time to therapeutic levels 10
• AdjBW formula: IBW + 0.4 × (TBW - IBW)

Pregnancy

• UFH does not cross the placenta and is safe in pregnancy 3
• Avoid preparations with benzyl alcohol preservative 2

Alternative Therapies

When to Choose Alternatives to UFH

LMWH (enoxaparin, dalteparin) is preferred over UFH for most VTE cases (grade 2C) 3:

• More predictable pharmacokinetics
• No monitoring required in most patients
• Lower HIT risk (approximately 0.2% vs. up to 5%)
• Once or twice daily subcutaneous dosing
• Contraindicated if CrCl <30 mL/min 3

Fondaparinux is another alternative:

• Synthetic pentasaccharide with predictable effect
• Once-daily subcutaneous dosing (2.5 mg for VTE)
• Virtually no HIT risk
• Contraindicated if CrCl <30 mL/min 3
• Never use to support PCI due to catheter thrombosis risk 1

Direct oral anticoagulants (DOACs): Rivaroxaban and apixaban can be initiated without parenteral bridging for VTE 3

When UFH Remains the Best Choice

• Severe renal impairment (CrCl <30 mL/min) 3
• High bleeding risk requiring rapid reversibility with protamine 4
• Cardiac surgery or PCI requiring precise titration 1, 2
• Critically ill patients with hemodynamic instability 7
• Pediatric patients at high bleeding risk (e.g., CSVT with hemorrhage) 4

Common Pitfalls and How to Avoid Them

1. Medication errors: UFH vials can be confused with catheter lock flush vials—always verify concentration before administration 2

2. Inadequate mixing: Invert IV bags at least 6 times to prevent heparin pooling 2

3. Delayed therapeutic anticoagulation: Using total body weight instead of adjusted body weight in obese or elderly patients prolongs time to therapeutic levels 10

4. Missing HIT: Failure to monitor platelets every 2-3 days from day 4-14 can miss this life-threatening complication 3

5. Inappropriate aPTT interpretation: Using manufacturer's normal range instead of institution-specific therapeutic range calibrated to anti-Xa levels 9, 6

6. Premature transition to warfarin: Must overlap UFH with warfarin for several days until INR is therapeutic for 2 consecutive days 2

7. Intramuscular injection: Never give UFH IM due to hematoma risk 2

8. Pre-analytical errors: Blood samples should be centrifuged within 1 hour and tested within 10 minutes (acceptable up to 1 hour) 6